ClinicalTrials.gg
CompletedNCT04457180Updated Oct 26, 2022

A Pharmacokinetic Interaction Study Between Apatinib Mesylate and Repaglinide or Bupropion in Advanced Solid Tumor Subjects

A Phase 1 interventional study of Apatinib Mesylate and Repaglinide in Advanced Solid Tumor, sponsored by Jiangsu HengRui Medicine Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2022-10-26.

Sponsored by Jiangsu HengRui Medicine Co., Ltd. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
18
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
All
01

Study summary

The primary objective of the study was to assess investigate the pharmacokinetic effects of Apatinib Mesylate on CYP2C8 Substrate Repaglinide or CYP2B6 Substrate Bupropion and metabolite Hydroxy bupropion in Advanced solid tumor subjects.

The secondary objective of the study was to assess the safety of Apatinib or/and Repaglinide and Bupropion.

02

Conditions studied

  • Advanced Solid Tumor
03

In context

Lead sponsor

Jiangsu HengRui Medicine Co., Ltd. is the lead sponsor of 573 studies on the registry; 88 are open to participants now.

Of its 10 completed or terminated interventional studies of FDA-regulated products, 1 (10%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age: 18-70 years old (Include both values).
  2. Patients with histopathologically or confirmed advanced solid tumor (not necessary to have ).
  3. or intolerant to standard treatment regimens, or no effective standard treatment regimens available, or the patients refused to use standard treatment plan.
  4. PS score: 0-1.
  5. Expected survival ≥ 3 months.
  6. Subjects have recovered from other treatments, at least 6 weeks since the last use of nitrosourea or mitomycin; at least 4 weeks since the last use of small molecule targeted therapy; at least 8 weeks since the last use of biological macromolecular therapy; at least 4 weeks since radiotherapy or surgery; at least 4 weeks since the last use of other cytotoxic or cytostatic drugs.
  7. Major organs must function normally, meeting the following criteria: (1) Hematology (no blood transfusion or blood products within the last 14 days, not corrected with G-CSF or other hematopoietic colony-stimulating factors):

    a. HB≥100 g/L; b. ≥1.5×109/L; c. ≥90×109/L; (2) Blood biochemistry: d. ≤ 1.25×; e. and AST≤2.5×ULN; f. ALP≤2.5×ULN; g. Serum Cr ≤ 1.5 × ULN or endogenous > 60 mL/min (Cockcroft-Gault formula); h. Albumin > 30 g/L.

  8. Sign the ICF voluntarily, have good compliance, corporate with follow-up visits, and follow the study requirements.

Exclusion criteria

Exclusion Criteria:

  1. Gastric cancer; tumors with risk of bleeding which researchers evaluated.
  2. Active (medically uncontrolled);
  3. Symptomatic third space fluid that cannot be controlled by drainage or other methods;
  4. Dysphagia, chronic diarrhea, or other factors affecting drug intake and absorption;
  5. Uncontrolled hypertension;
  6. Heart rate \< 60, Grade II or greater myocardial ischemia or myocardial infarction, uncontrolled arrhythmias ( ≥ 450 ms in males and ≥ 470 ms in females);
  7. to Repaglinide and Bupropion;
  8. Class III-IV cardiac insufficiency or (LVEF) \< 50% by echocardiography;
  9. Abnormal coagulation function ( > 1.5 or prothrombin time (PT) > + 4 s or APTT > 1.5 ULN), bleeding tendency or who are currently receiving thrombolytics;
  10. Arterial/venous thrombosis within 6 months prior to the first dose;
  11. Hemorrhage and thrombophilia;
  12. Major surgery or with severe traumatic injury, fracture, or ulcer within 4 weeks prior to the first dose;
  13. Abdominal fistula, gastrointestinal perforation or abdominal abscess within 6 months prior to the first dose;
  14. Urine protein ≥ ++ and 24 h urine protein ≥ 1.0 g as indicated by urinalysis;
  15. Treatment with for more than 50 days, or requires chronic steroid use;
  16. Use of study drugs in other clinical trials within 4 weeks prior to the first dose;
  17. Use of drugs affected gastric acid secretion or inhibitors of cytochrome enzyme CYP2C8、CYP2B6、CYP2D6、 or transporter OATP1B1, or traditional Chinese medicine within 2 weeks prior to the first dose; use of inducers of metabolic enzymes CYP2C8, CYP2B6, CYP2D6, or CYP3A within 4 weeks prior to the first dose;
  18. Unable to hold drugs that may prolong QT interval during the study (such as antiarrhythmics);
  19. Habitual alcohol consumption or smoking, tested positive for alcohol screening, and unable to abstain from smoking and alcohol during the trial;
  20. Other factors affecting drug absorption, distribution, metabolism, excretion within 48 hours;
  21. Active (positive HBsAg and HBV-DNA≥104 or 2000IU/ml) or C ( antibodies are positive and HCV-RNA is above the detection limit of the analytical method);
  22. Active infection requiring antimicrobial therapies (such as antibacterials, antivirals, or antifungals);
  23. Immunodeficiency, including positive results of test or other acquired or congenital immunodeficiencies, or a history of organ transplantation;
  24. Allergic constitution, or known allergies to drug components used in this study;
  25. Pregnant or lactating women;
  26. Other factors that may affect the progress or the conclusion of the study, as determined by the investigator.
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
18 participants (actual)

Study arms

  • Experimental
    treatment

    In phase A, subjects receiving a single dose of Repaglinide orally on day 1 , a single dose of Bupropion orally on day 2 and wash-out for 10 days, then apatinib once daily will be conducted on D5 through D16 # In addition, In phase B, subjects receiving a single dose of Repaglinide (in combination with apatinib) orally on day 12 , a single dose of Bupropion (in combination with apatinib) orally on day 13.

    Drug: Apatinib Mesylate · Drug: Repaglinide · Drug: Bupropion

Interventions

  • Apatinib will be administered daily from on D5 through D16

  • Repaglinide will be administered daily on D1 and D12

  • Bupropion will be administered daily on D2 and D13

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics parameter: Cmax of digoxin

    Peak Plasma Concentration (Cmax) of digoxin

    Time frame: through study completion, an average of 16 days

  2. Pharmacokinetics parameter: AUC of digoxin

    Area under the plasma concentration versus time curve (AUC) of digoxin

    Time frame: through study completion, an average of 16 days

Secondary outcomes

  1. Pharmacokinetics parameter: Tmax of digoxin

    Time of maximum observed concentration (Tmax) of digoxin

    Time frame: through study completion, an average of 16 days

  2. Pharmacokinetics parameter: T1/2 of digoxin

    Half time (T1/2) of digoxin

    Time frame: through study completion, an average of 16 days

  3. Pharmacokinetic parameters CL/F of digoxin

    Total body clearance for extravascular administration (CL/F) of digoxin

    Time frame: through study completion, an average of 16 days

  4. Pharmacokinetics parameter: Vz/F of digoxin

    Volume of distribution (Vz/F) of digoxin

    Time frame: through study completion, an average of 16 days

  5. Number of participants with treatment-related adverse events as assessed by CTCAE v5.0

    An adverse event is any untoward medical occurrence in a patient or clinical study participant criteria

    Time frame: through study completion, an average of 16 days

07

Study locations

1 site
  • The First Affiliated Hospital of University of Science and Technology of China
    Hefei, Anhui 201203, China
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2020 to primary completion in May 2021, 6 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 30, 2020
First posted
Jul 7, 2020
StartActual
Nov 16, 2020
Primary completionActual
May 20, 2021
CompletionActual
Jun 19, 2021
Last update
Oct 26, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 26, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04457180
Responsible party
Sponsor
First posted
Jul 7, 2020
Start date
Nov 16, 2020
Primary completion
May 20, 2021
Completion
Jun 19, 2021
Last update
Oct 26, 2022

Study contacts

pan yueyin, Ph.D.
principal investigator · The First Affiliated Hospital of University of Science and Technology of China

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Apatinib · Repaglinide · Bupropion

Start the discussion